MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$128,630,000
Loss from continuing
operations
-$128,630,000
Income tax (benefit)
expense
-$12,184,000
Segment adjusted income
(loss) from operations...
$112,237,000
Cost of
revenues-generic...
$70,760,000
Selling and
marketing-branded...
$60,183,000
Cost of
revenues-sterile injectables...
$56,292,000
Segment adjusted income
(loss) from operations...
$21,707,000
Adjusted research and
development-sterile injectables...
$17,894,000
Cost of
revenues-branded...
$16,781,000
Adjusted research and
development-branded...
$11,739,000
General and
administrative-branded...
$8,551,000
Cost of
revenues-international...
$6,141,000
Selling and
marketing-sterile injectables...
$3,850,000
General and
administrative-sterile injectables...
$3,670,000
General and
administrative-generic...
$2,984,000
General and
administrative-international...
$2,938,000
Selling and
marketing-international...
$2,486,000
Adjusted research and
development-generic...
$2,001,000
Selling and
marketing-generic...
$1,632,000
Segment adjusted income
(loss) from operations...
$1,422,000
Loss from continuing
operations before income...
-$140,814,000
Total revenues, net
$392,833,000
Segment adjusted income
(loss) from operations...
-$10,435,000
Cost of revenues
$295,403,000
Selling, general and
administrative
$149,041,000
Interest expense, net
-$52,670,000
Research and development
$31,634,000
Acquired in-process
research and development
$2,536,000
Other expense, net
-$1,028,000
Acquisition-related and integration
items, net
$1,015,000
Litigation-related and other
contingencies, net
-$320,000
Back
Back
Income Statement
source: myfinsight.com
Endo, Inc. (NDOI)
Endo, Inc. (NDOI)